<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02028312</url>
  </required_header>
  <id_info>
    <org_study_id>CEI.HER-002</org_study_id>
    <nct_id>NCT02028312</nct_id>
  </id_info>
  <brief_title>A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edward Holland, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Holprovision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study to evaluate the impact of Lotemax® Gel (loteprednol etabonate ophthalmic gel&#xD;
      0.5%) on the initiation of Restasis® (cyclosporine ophthalmic emulsion 0.05%) therapy in&#xD;
      subjects with dry eye.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Per Sponsor&#xD;
  </why_stopped>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fluorescein corneal staining scores</measure>
    <time_frame>60 Days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lissamine green conjunctival staining</measure>
    <time_frame>60 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>Loteprednol etabonate + Restasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loteprednol Etabonate Ophthalmic Gel 0.5%, BID 30 days Restasis, BID 45 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artificial Tears + Restasis</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Artificial Tears, BID 30 days Restasis, BID 45 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loteprednol etabonate</intervention_name>
    <arm_group_label>Loteprednol etabonate + Restasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artificial Tears</intervention_name>
    <arm_group_label>Artificial Tears + Restasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Restasis</intervention_name>
    <arm_group_label>Artificial Tears + Restasis</arm_group_label>
    <arm_group_label>Loteprednol etabonate + Restasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent prior to any study-related procedures and provide&#xD;
             Health Insurance Portability and Accountability Act (HIPAA) authorization.&#xD;
&#xD;
          2. Are between the ages of 21 and 80 inclusive.&#xD;
&#xD;
          3. Have not worn contact lenses for at least 1 month prior to the study and agrees not to&#xD;
             wear contact lenses during the study.&#xD;
&#xD;
          4. Have been on stable oral medications for 1 month prior to the study.&#xD;
&#xD;
          5. Are in generally good and stable overall health.&#xD;
&#xD;
          6. Are a woman of child bearing potential (WOCBP) who is not pregnant or lactating and&#xD;
             not sexually active (i.e. abstinent) at Visit 1 and willing to remain so through Visit&#xD;
             4. Alternatively, a WOCBP who is not abstinent must have been using an acceptable&#xD;
             method of birth control for at least 4 weeks prior to Visit 1 and throughout the&#xD;
             study.&#xD;
&#xD;
          7. Are women who have undergone one of the following sterilization procedures at least 1&#xD;
             month prior to Visit 1:&#xD;
&#xD;
               1. Bilateral tubal ligation&#xD;
&#xD;
               2. Hysterectomy&#xD;
&#xD;
               3. Hysterectomy with unilateral or bilateral oophorectomy.&#xD;
&#xD;
               4. Bilateral oophorectomy&#xD;
&#xD;
          8. Are likely to comply with the eye drop regime, study guidelines, and study visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have a history of Stevens-Johnson Syndrome or ocular pemphigoid.&#xD;
&#xD;
          2. Have had punctual plugs inserted or removed; or punctual cautery 3 months prior to&#xD;
             Visit 1/Screening and Baseline Visit and throughout the study.&#xD;
&#xD;
          3. Have had intra-ocular surgery within 6 months prior to the Visit 1/Screening and&#xD;
             Baseline Visit.&#xD;
&#xD;
          4. Have a history of liver disease.&#xD;
&#xD;
          5. Be pregnant or lactating.&#xD;
&#xD;
          6. Have severe clinical vitamin deficiencies or a history of vitamin overdose.&#xD;
&#xD;
          7. Have a highly variable vitamin intake.&#xD;
&#xD;
          8. Wear contact lenses.&#xD;
&#xD;
          9. Have unstable use of systemic or topical medications known to create dry eye.&#xD;
&#xD;
         10. Have corneal pathology, which could, of itself, cause an ocular surface disorder.&#xD;
&#xD;
         11. Have used glaucoma medications, topical or oral within 30 days of Visit 1/Screening&#xD;
             and Baseline Visit.&#xD;
&#xD;
         12. Have unstable diabetes mellitus.&#xD;
&#xD;
         13. Have an allergy or sensitivity to Lotemax® Gel, Restasis®, or non-preservative&#xD;
             artificial tears.&#xD;
&#xD;
         14. Have used topical steroids or Restasis® within 1 month prior to the Screening and&#xD;
             Baseline Visit and throughout the study, except the study medication provided per the&#xD;
             protocol.&#xD;
&#xD;
         15. Have a condition for which steroid use would be contraindicated (e.g. viral&#xD;
             infection).&#xD;
&#xD;
         16. Use other topical ocular agents other than tear replacements within 1 week prior to&#xD;
             the Screening and Baseline Visit and throughout the study.&#xD;
&#xD;
         17. Have been exposed to an investigational drug within the preceding 30 days.&#xD;
&#xD;
         18. In the opinion of the investigator or study coordinator, be unwilling or unable to&#xD;
             comply with the study protocol or unable to successfully instill eye drops.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>January 3, 2014</study_first_submitted>
  <study_first_submitted_qc>January 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Holprovision</investigator_affiliation>
    <investigator_full_name>Edward Holland, MD</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Dry Eye</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

